XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta). One of the patents covers methods of treating Type 2 diabetes with high affinity antibodies and antibody fragments that bind to IL-1 beta, including XOMA 052. The high affinity antibodies, such as XOMA 052, offer potential advantages in Type 2 diabetes because they may provide greater potency, less frequent dosing, reduced dose levels, and manufacturing efficiencies.

Additional claims in this patent relate to methods of reducing or preventing complications or conditions associated with Type 2 diabetes including retinopathy, renal failure, wound healing and cardiovascular disease, with these high affinity IL-1 beta antibodies. The patent also includes claims that relate to methods of treatment of Type 2 diabetes with high affinity IL-1 beta antibodies in conjunction with additional agents.

A second patent covers methods of treating IL-1 related inflammatory diseases, including rheumatoid arthritis and osteoarthritis, with XOMA 052 and other antibodies and antibody fragments with similar binding properties for human interleukin-1 beta (IL-1 beta).

The patents expire in 2027 (U.S. 7,695,718) and 2026 (U.S. 7,695,717), respectively. With these patents, the intellectual property portfolio for XOMA 052 includes four issued patents in the U.S. and one granted patent in Europe. Additional applications are pending in the U.S. and other countries.

"It is remarkable that targeting one component of the IL-1 pathway, as we have with our high affinity IL-1 beta antibody XOMA 052, may address a broad range of diseases that have inflammation as a common disease cause," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer.   "The issuance of these patents highlights XOMA's innovative research with IL-1 beta antibodies and in particular our pioneering role in applying IL-1 beta targeting to the treatment of Type 2 diabetes."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy